🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Egypt / NCT07702149
Recruiting Not applicable

Diet Restiction in Subjects With Behcet Disease and Complaint of Tinnitus

NCT07702149 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-06-04
Last updated
2026-07-14

Condition(s) studied

Behcet DiseaseObesitySubjective Tinnitus

Investigational drug(s) / intervention(s)

diet restriction

diet restriction: twenty subjects with behcet disorder, excess weight, complaint o tinnnitus will follow low calorie diet 12-week regeim.

Study summary

otogic problems are varied in bechet disorder, tinnnitus is one of these problems. obesity may increase this probelm

Eligibility

Sex
ALL
Min age
40 Years
Max age
55 Years
Healthy volunteers
No
Inclusion Criteria: * behcet disease * obesity * subjective tinnitus (bilateral) Exclusion Criteria: * other autoimune diseases * refusal to participate

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Cairo University Giza Dokki Recruiting
Cairo University Dokki Giza Governorate Recruiting

More Cairo University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07702149 on ClinicalTrials.gov ↗ ← All trials in Egypt